Jaguar Health (JAGX) Q2 FY26 earnings call

Jaguar Health is undergoing a strategic transformation, shifting its human development focus entirely to rare disease GI indications, specifically Intestinal Failure (IF) with its novel crofelemer formulation. The company secured significant non-dilutive capital through the out-licensing of Mytesi, enabling a sharp focus on its pivotal MVID program, which has shown compelling clinical data and is on an accelerated regulatory path. This strategic pivot aims to unlock substantial value in a market significantly larger than its previous HIV focus, while also expanding its animal health offerings.